Form 4: Doximity Director Cabral Granted 3,221 RSUs

Doximity, Inc. director Timothy S. Cabral received a grant of 3,221 restricted stock units as part of the company's non-employee director compensation policy.

Summary

• Timothy S. Cabral, a Director of Doximity, Inc. (DOCS), was granted 3,221 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on August 28, 2025.
• The RSUs were granted at a price of $0, consistent with a compensation grant.
• This transaction was made pursuant to the Issuer's non-employee director compensation policy.
• The RSUs will vest in full on the earlier of (i) the first anniversary of the grant date (August 28, 2026) or (ii) the Issuer's next annual meeting of stockholders, contingent on Mr. Cabral's continued service as a director.
• Following this transaction, Mr. Cabral beneficially owns 9,581 shares of Class A Common Stock directly.
• The transaction was reported on September 2, 2025, and indicated as made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports a routine compensation grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments for the company. It's a standard, expected event.

Positives

• The grant of restricted stock units aligns the director's financial interests with those of the shareholders, encouraging long-term commitment and performance.
• The transaction is part of a pre-established non-employee director compensation policy, indicating structured and transparent governance practices.

Future Outlook

The vesting schedule for the restricted stock units implies an expectation of Timothy S. Cabral's continued service as a director through at least the first anniversary of the grant date or the next annual meeting of stockholders, whichever comes first.

Industry Context

The grant of restricted stock units to non-employee directors is a common practice across various industries, including healthcare technology, to attract and retain qualified board members and align their incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of non-employee director compensation is a widely adopted practice among publicly traded companies, particularly in the technology and healthcare sectors, including peers like Teladoc Health (TDOC) or Veeva Systems (VEEV).
• Granting equity at a $0 price for compensation purposes is standard for RSUs, which represent a contingent right to receive shares upon vesting, rather than a purchase.
• Vesting schedules tied to continued service and specific timeframes (e.g., one year or next annual meeting) are typical for director equity awards, ensuring commitment and aligning interests over a relevant period.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value creation, as the value of the RSUs is tied to the company's stock performance.
• Employees: No direct impact mentioned, but consistent compensation practices for leadership can contribute to overall company stability and morale.

Next Steps

• Timothy S. Cabral's continued service as a director of Doximity, Inc. until the vesting conditions are met.
• Vesting of the 3,221 restricted stock units on the earlier of August 28, 2026, or the company's next annual meeting of stockholders.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of restricted stock units to a non-employee director as part of their compensation. Such grants are standard practice and do not typically provide new information that would alter an investment thesis for Doximity, Inc. The transaction aligns the director's interests with shareholders but does not indicate a significant change in the company's operational or financial outlook, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Doximity, DOCS, Timothy Cabral, Form 4, RSU, Restricted Stock Units, Director Compensation, Insider Transaction, Equity Grant